Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals Company

Shuaige Wang

Joanne M Smallheer

Jennifer X Qiao

Mimi Lifen Quan

Ruth Richmond Wexler

Prabhakar Kondaji Jadhav

Zilun Hu

Irina C Jacobson

Donald J Pinto

Wei Han

Gregory S Bisacchi

Suanne Nakajima

The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L, L, X, X, X, Xand W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Biarylmethyl indolines and indoles as antithromboembolic agents

The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I:or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors

Isoxazoline fibrinogen receptor antagonists

This invention relates to novel isoxazolines and isoxazoles of formula (I):

Growing community of inventors

West Chester, PA, United States of America

Shuaige Wang